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Monitoring current illicit drug trends and consumption rates of pharmaceuticals using a non-
invasive collection technique is needed to address the present drug use and the growing drug 
epidemic.  Reliance on self-reporting drug use surveys is not always a practical measure of illicit 
drug use.  Wastewater analysis has been used globally as a targeted method for monitoring the 
consumption of specific illicit drugs.  Current existing analytical techniques for wastewater 
analysis focus on the use of targeted liquid chromatography-mass spectrometry (LC-MS) based 
techniques.  Few gas chromatography (GC) procedures exist for wastewater analysis, and those 
that do concentrate their methods on a single class of drugs operating their mass spectrometer 
(MS) in selective ion monitoring (SIM) mode.  This study aims to develop an untargeted, 
underivatized, full scan gas chromatography-mass spectrometry (GC/MS) method for the 
analysis of wastewater.  Solid phase extraction (SPE) was performed with UCT mixed mode, 15 
mL Clean Screen DAU columns with 500 mg sorbent to extract a 500 mL wastewater sample.  
Sample extracts were reconstituted in ethyl acetate and analyzed on a Shimadzu GCMS-QP2020 
gas chromatograph-mass spectrometer (GC/MS) installed with an Agilent J&W HP-5MS (30 m 
× 0.25mm, 0.25 µm) column. Injection volume, flow rate, oven temperature, and ion source scan 
rate were optimized to develop an untargeted full scan method for the detection of 
pharmaceuticals. Calibration curves were developed for 42 targeted drugs.  A 1 µL sample 
volume is run with a splitless injection utilizing helium as the carrier gas and the instrument 
operated in constant flow mode at a rate of 1.0 mL/min.  The GC oven program is held at the 
initial temperature of 70°C for 2 min then ramped at 15°C/min to 300°C and held for 10 min for 
a total run time of 27.33 min.  The injection port, transfer line, and source were set at 250°C, 
280°C, and 200°C respectively.  The MS operated in full scan mode, scanning ions from 35-550 
m/z at an event time of 0.20 seconds from 3.50-27.33 minutes. Out of a 42 drug panel, over 75% 
of the generated calibration curves were suitable for quantitation with coefficients of 
determination greater than 0.9875.  Limits of detection for most drugs ranged from 0.10-1.0 
ng/mL, on par with many targeted liquid chromatography methods.  The optimized untargeted 
method is able to detect a wide range of compounds in addition to those in the drug panel. The 
untargeted full scan MS method supports monitoring a wider range of pharmaceuticals 
overlooked in traditional targeted waste water methods such as changing trends in novel 
psychoactive substances. 
 




The Substance Abuse and Mental Health Services Administration’s (SAMHSA) 
2018survey results show an increase in the use of nearly every drug class across all surveyed age 
groups (SAMHSA, 2019).  Almost 8%, or 19.3 million people, of the United States adult 
population (≥18), suffer from a substance use disorder (SUD), and nearly 40% of their SUDs are 
struggling with illicit drugs (SAMHSA, 2019).  Since the early 1990’s, over prescribing of pain 
management drugs has led the United States into the middle of an opioid epidemic.  It is 
estimated that between 21-29% of patients prescribed opioids will misuse them (Vowles et al., 
2015).  Even more alarming is in the period of one year, 2016-2017, more populous cities 
experienced a 54% increase in opioid overdoses, and a 70% increase in midwestern states 
(Vivolo-Kantor et al., 2018).  However, while developed strategies to combat this epidemic have 
been successful in reducing illicit heroin use by over 2 million users from 2017-2018, 
prescription opioids, such as methadone and buprenorphine, abuse has continued to rise 
(SAMHSA, 2019).  Additionally, marijuana, stimulant, and hallucinogenic drug use has 
significantly (statistically significant at the 0.05 level) increased in use by the ≥26 age population 
over this same time frame (SAMHSA, 2019).   
Over the last ten years the Drug Enforcement Administration (DEA) has reported an 88% 
decrease in domestic laboratory production of methamphetamine, yet during this time high purity 
(≥95%) Mexican border drug seizures have increased nearly tenfold, and overdose deaths 
involving methamphetamine have increased by 500%.  Overdose (OD) deaths involving most 
illicit substances have continued to rise steadily since 1999, but nearly a 30% decrease from 
2015-2019 in OD deaths involving solely heroin has been reported (DEA, 2019).  Prescription 
pharmaceutical OD deaths also continue to rise.  From 1999-2017, OD deaths involving 
 
prescription antidepressants, psychostimulants, benzodiazepines, and opioids have risen 100-
300%.  Scarier yet, OD deaths involving fentanyl or fentanyl analogs have increased over 1000% 
in the last five years (DEA, 2019).   
The American Addiction Centers (AAC) report that current admissions to drug treatment 
programs have risen over the last three years while government funding for these programs has 
decreased.  Almost 65% of treatment facilities received government funding in 2002 but since 
then this has decreased steadily leading to less than 50% of treatment centers receiving 
government funding today (AAC 2019).  This has resulted in a decrease in non-profit free 
treatment programs and a 21% increase in for-profit treatment programs since 2004 (AAC 2019).  
In the latest data from 2017, the Center of Disease Control and Prevention (CDC), reported a 
9.6% increase in deaths attributed to overdose in the United States at over 70,000 deaths.  
Utilizing Healthcare Cost and Utilization Project’s (HCUP) Nationwide Emergency Department 
Samples (NEDS) the CDC generated data accounting for nearly one million non-fatal OD cases 
treated by emergency departments in 2017 alone (Vivolo-Kantor et al. 2017).   In 2008, 
SAMHSA stated that for prescription painkillers alone, for every overdose death there are over 
30 non-fatal overdoses and over 800 non-medical abusers (SAMHSA, 2010).  Given the increase 
in drug consumption and overdose cases, a comprehensive, non-invasive method for monitoring 
community drug use is necessary.   
Current monitoring techniques as practiced by agencies like SAMHSA, the DEA, the 
CDC are no longer an effective or accurate way of monitoring real time drug trends.  Self-
reporting population surveys monitoring drug use is an economical choice that has significant 
limitations.  Self-reporting can lead to bias, misrepresentation, and underreporting of the true 
frequency of drug use.  Misrepresentation occurs due to the negative stigma surrounding the use 
 
of illicit substances and abusing prescription pharmaceuticals.  Additionally, in many instances, 
illicit drug users do not know exactly what drugs they have been using, reporting solely heroin 
use when in actuality they have been using fentanyl, a fentanyl analog, or some polydrug 
mixture.  Therefore, surveys are often ignored by these users or falsified and the information 
given is not an accurate representation of the true value.  Self-reporting also lends itself to being 
open to population bias and is dependent on the area surveyed to be an accurate representation of 
a larger population.  Issues arise when urban areas are overly represented in these surveys 
leading to the belief that illicit drug use is solely a problem for larger cities (Banta-Green et al., 
2009; van Nuijs et al., 2009b).  Lastly, the greatest issue with survey-based data is the rate at 
which it becomes available.  Often, surveys are done on a biennial basis, with resulting data 
processed and released the following year.  Thus, by the time data is made available it is nearly 
three years old and no longer an accurate representation of the current state of affairs.    
Similarly, using overdose statistics put out by the CDC lends itself to some of the same 
issues as surveys.  Although it avoids the bias that occurs with self-reporting, the data is 
collected over an extended period of time and not published or made available for over a year 
after collection.   In many instances, hospitals are not required to report overdoses and, 
oftentimes, treat the symptoms of an overdose without knowing the underlying cause leading to 
the possibility of misreported, or underreported, information.  In cases resulting in death, 
accidental overdose information is often reported as an unspecified overdose.  Over a six year 
study in Indiana, it was shown that over 57% of overdose death cases were attributed as 
unspecified overdoses (Lowder et al. 2018).  Overdose statistics also do not account for 
overdoses that occur and are treated at home.  Naloxone can be prescribed as a treatment for an 
opioid overdose, but does not necessarily mean it is needed or used.  Arizona, California, Ohio, 
 
Rhode Island, Vermont, and Virginia all require physicians to co-prescribe, or offer to co-
prescribe, naloxone in situations where prescribed opioid medication exceeds a certain dosage.  
Therefore, monitoring prescriptions is also not an accurate way of monitoring drug use.  
Using arrest records for monitoring drug use can also lead to an inaccurate representation 
of population.  The Federal Bureau of Investigation (FBI) compiles annual arrest records based 
on a multitude of charges, of which drug offenses is one category.  The Uniform Crime 
Reporting (UCR) statistics are an excellent tool for identifying isolated drug use but only 
accounts for those arrested, not the entire scope of communal drug use.  Monitoring drugs based 
solely on arrest does not account for users who are never arrested and also includes repeat 
offenders multiple times.  Reported cases encompass both sales/distribution as well as possession 
charges.  Misdemeanor possession charges have risen every year for the last ten years (FBI 
2019).  Simple possession charges are sometimes reported as “possession of a controlled 
substance” where the substance is either unidentified or categorized as “other,” making the 
information unreliable in identifying specific drug trends.  The National Forensic Laboratory 
Information System (NFLIS) aids this by keeping records of the number of cases, amounts, and 
types of drugs submitted.  However, not all crime labs report their case statistics to NFLIS, 
leading to a population bias.  Arrest monitoring also suffers from the same delay as other long-
term analysis in that information is not made available till a year later.  Additionally, the 156 
participating drug laboratories reported having nearly 300,000 cases in backlog, meaning stats 
obtained from the current years report does not fully reflect current drug trends (DEA 2019).           
A more comprehensive method for the accurate monitoring of drug use could be the 
testing of municipal wastewater.  Analyzing water sources for the presence of drugs and other 
compounds is hardly a new concept with extraction and instrumental techniques dating back to 
 
more than fifty years ago.  Many early methods were developed for the detection of pesticides in 
natural waterways (Abbott et al., 1967; Hindin et al., 1962; Leoni, 1971; Teasley et al., 1963).  
Adapting these methods for testing wastewater for pharmaceutical consumption was first 
theorized in 2001 by Environmental Protection Agency (EPA) scientist Christopher Daughton 
(Daughton, 2001).  According to the Organization for Economic Co-operation and Development 
(OCED) more than 75% of the United States population has plumbing that is serviced by a 
wastewater treatment plant (WWTP), with this percentage rising dramatically in more urban 
settings.  Each WWTP services a designated area and therefore measuring concentrations of 
influent wastewater provides a more accurate representation of localized drug consumption. 
Samples from WWTP can be collected in bulk and enable  real time tracking of drug trends on a 
more frequent basis.  Some WWTP can be reluctant to provide samples, or allow individuals to 
collect them, citing possible ethical or privacy issues.  Though this may have some merit in 
regards to sampling of smaller populations such as manholes, schools, or individual sewer lines, 
utilizing wastewater to monitor large populations does not pose any ethical concerns as 
individualization is impossible (Hall et al., 2012).  Additionally, not unlike garbage or solid 
waste, once an individual flush their bodily excretions it can be considered discarded and privacy 
is no longer expected, therefore can be collected without obtaining a warrant (Hering, 2009).  
However, drug levels in wastewater can be contributed by more than just drug consumption and 
excretion (Figure 1).  In addition to user excretions, pharmaceutical disposal as well as 
clandestine laboratory waste may contribute to elevated levels in certain WWTPs, however, it is 
suspected that this contribution would be minor compared to user contributions.   
The primary goal of WWTPs is to render wastewater safe for environmental 
reintroduction. Treatment consists of a six-step process: screening, primary clarification, 
 
biological processing, secondary clarification, filtration, and disinfection.  WWTPs may use all 
or some of these techniques (Rao et al., 2013).  Raw incoming wastewater, or influent, is initially 
screened and filtered utilizing mesh or bar screens to remove large solid material.  Heavy 
particles of sand or grit are also removed by vortexing, forcing these particles to the bottom.  
Primary clarification removes suspended semisolids, or sludge, from the wastewater by simple 
sedimentation.  Remaining sludge particulate and dissolved organic solids are removed by 
biological processing in which the water is treated by aeration and the introduction of 
microorganisms that digest these solids.  The introduction of these microbes results in cellular 
flocs which require removal via a secondary clarification step.  Wastewater is then filtered, 
typically using a simple carbon filter, and sterilized using ultraviolet radiation, ozonation, or 
chemically by chlorination/dichlorination.  Post treated wastewater, or effluent, is then 
reintroduced into the environment by dumping into natural waterways or used for irrigation (Rao 
et al., 2013; Stephens et al., 2009). 
The use of wastewater for illicit substance monitoring has been performed globally; 
including New Zealand, Australia, China, South Africa, many countries in Europe, as well as the 
United States, for over the last twenty years, employing a variety of extraction and instrumental 
analysis techniques.  In 2011, a critical review was published evaluating many of these analytical 
techniques and their results focusing on cocaine, amphetamine, cannabinoids, and opiates (Van 
Nuijs et al., 2011).  A majority of these techniques employ the use of a solid phase extraction 
(SPE).  Solid phase extractions can be modified both in the sorbent material as well as the 
extraction scheme used.  This allows for extremely clean and compound specific extractions.  
SPE cartridges are commercially available with class specific sorbent materials.  In Van Nuijs’ 
2011 review he published a wide variety of different compound specific extractions (Bijlsma et 
 
al., 2009; Boleda et al., 2007; Bones et al., 2007; Castiglioni et al., 2006; Gheorghe et al., 2008; 
González-Mariño et al., 2009; Huerta-Fontela et al., 20017; Hummel et al., 2006; Kasprzyk-
Hordern et al., 2008; Mari et al., 2009; Postigo et al., 2008a; van Nuijs et al., 2009a; van Nuijs et 
al., 2011; Zuccato et al., 2005), columns used, and extraction schematics.  Methods described in 
these studies used 5-500 milliliters (mL) of sample, depending on the sample type and analysis 
being performed.  Since 2011 additional SPE methods have been developed (Table 1).  Fewer 
extraction methods employ the use of a liquid-liquid extractions (Arbeláez et al., 2014; Baker et 
al., 2012; Teasley et al., 1963) due large sample and solvent volumes and the greater likelihood 
of contamination.  SPE is typically performed within three days of sample collection, or 
immediately after samples thaw from frozen to prevent drug metabolism and degradation.  Due 
to particulate matter, samples are better suited for SPE if they have been filtered and/or 
centrifuged prior to extraction.  In rarer instances no extractions were performed and raw 
wastewater samples were injected directly onto the instrument for analysis (Chiaia et al., 2008). 
Historically, analysis of extracted samples are commonly analyzed by either high-
performance liquid chromatography (HPLC) or ultra-high-performance liquid chromatography 
(UHPLC) coupled to a mass spectrometer (MS).  Numerous LC-MS methods have been 
developed using various columns and solvent systems based on the analytes of interest (Table 2).  
Rarely are these methods developed as a full scan but instead are developed in specific drug 
panels based on class of drug.  Therefore, these methods are operated in one of two modes, 
selected reaction monitoring (SRM) or multiple reaction monitoring (MRM) solely focusing on 
specific ions for a select group of analytes.   Modern LC systems have the advantage of being 
extremely sensitive and allow for greater injection volumes, thus, require a less concentrated 
injection resulting in reduced sample volumes.   
 
Gas chromatography (GC) mass spectrometry (MS) is a less common analytical 
technique utilized for the analysis of wastewater.  Fewer GC methods exist compared to their LC 
counterparts possibly due to their decreased sensitivity.  GC requires far less startup cost than LC 
and the utilization of a carrier gas instead of solvent based mobile phases lends it to vastly 
cheaper maintenance, operation, and waste disposal fees.   Although, some GC methods for the 
analysis of wastewater have been developed (Table 3).  These methods utilize the same sample 
prep, sample volume, and SPE extraction techniques as LC analysis but rely on an additional 
derivatization step.  The addition of this derivatization has both added time and cost to the 
wastewater analysis.  Furthermore, GC methods are typically performed having a targeted 
analysis operating in selected ion monitoring (SIM) mode.  This is done in an effort to negate 
background, sample, and atmospheric interferences.  SIM mode however narrows the focus of 
the GC limiting the number of compounds the method can detect, whereas operating in scan 
mode detects all possible analytes.   
The development of an untargeted, underivatized, full scan GC/MS method for the 
analysis of wastewater is necessary for the accurate monitoring of communal drug use.  This will 
allow for the detection of a wide array of pharmacologically active compounds, including 
prescription medicines, over-the-counter therapies, and illicit drugs. A method for quantitating 
42 common drugs will also be developed.   
Materials & Methods 
Sample Collection 
Wastewater samples were collected from nine partnering WWTPs throughout central and 
eastern Virginia.  Both influent and effluent samples were collected from each WWTP as well as 
a sample from natural waterways where samples were reintroduced to the environment.  A 
 
minimum of 500 mL of each sample (influent, effluent, reintroduced) were collected and marked 
with the WWTP collection site as well as the date collected.  Samples were collected in clean 
one-liter plastic bottles, free of preservatives, and stored in the freezer (≤-15°C) until analysis 
could be performed.  In the cases where multiple bottles of sample were collected one was 
placed in the freezer and one was stored in the refrigerator (~4°C) for stability analysis. 
Sample Preparation  
Prior to extraction 500 mL sample aliquots were allowed to reach room temperature and were 
then buffered to pH 6.0 ± 0.10 with the use of buffering salts.  Sodium phosphate monobasic 
monohydrate and sodium phosphate dibasic heptahydrate were obtained from Fisher Scientific 
(Fisher, Hampton, New Hampshire, USA) and used to adjust samples to have a molarity of 0.10 
and a pH of 6.0.  To each 500 mL sample 6.28 grams of sodium phosphate monobasic 
monohydrate and 1.21 grams of sodium phosphate dibasic heptahydrate were added to achieve a 
0.1M phosphate buffered solution.  Salts were added to each sample and shaken until completely 
dissolved.  The pH of samples was evaluated on a Thermo Orion Star (Thermo, San Jose, 
California, USA) benchtop pH meter calibrated daily using a three-point calibration curve with 
pHs of 4, 7, and 10 utilizing calibration buffers from Fisher Scientific.  After buffering, if 
samples tested pH fell outside the 6.0 ± 0.10 range they were adjusted using 0.1M hydrochloric 
acid (HCl) or 0.1M ammonium hydroxide (NH4OH).  The HCl or NH4OH solutions were added 
dropwise to the sample which was shaken vigorously and allowed to settle prior to the pH being 
retested.  Calibration working solutions and internal standard (IS) working solutions were 
prepared from 1.0 mg/mL drug standard (Table 4) certified reference materials purchased from 
either Cerilliant (Cerilliant, Round Rock, Texas, USA) or Cayman Chemical (Cayman, Ann 
Arbor, Michigan, USA).  Calibrators were fortified at concentrations of 0.1, 0.2, 0.4, 1.0, 2.0, 
 
3.0, and 4.0 ng/mL or 50, 100, 200, 500, 1000, 1500, and 2000 ng total for each drug.  All 
calibrators, samples, and controls were also fortified with 1.0 ng/mL, or 500 ng total, of two 
different deuterated internal standards, methadone-d9 and phenobarbital-d5.  After being 
fortified, buffered samples falling within the proper pH range (5.9-6.1) were then ready for 
extraction. 
Solid Phase Extraction 
The SPE operated using a UCT Positive Pressure Manifold System (United Chemical 
Technologies, Bristol, Pennsylvania, USA) connected to an Airgas nitrogen tank (Airgas, 
Richmond, Virginia, USA).  The SPE extraction was performed using UCT mixed mode, 15 mL 
Clean Screen DAU SPE columns with 500 mg sorbent.  Extraction solvents; methanol, acetic 
acid, ethyl acetate, methylene chloride, isopropanol, and ammonium hydroxide were all obtained 
from Fisher Scientific, 98% pure hexanes was obtained from Alfa Aesar (Alfa Aesar, Haverhill, 
Massachusetts, USA).  SPE columns were conditioned with 3 mL of methanol, 3 mL of ultra-
pure water, followed by 3 mL of 0.10M sodium phosphate buffer pH 6.0.  All conditioning steps 
were allowed to flow through via gravity.  The buffered 500 mL sample was then loaded on 
column 10-15 mL at a time and at a flow rate of 10 mL/min.  Columns were then washed with 3 
mL of ultra-pure water followed by 2 mL of 1.0M acetic acid passed through at 1 mL/min.  After 
washing columns were then dried at 35 psi for a minimum of 15 minutes (min) with additional 
time if columns were not fully dry.  Once dry columns were washed with 3 mL hexanes prior to 
elution of the acidic fraction with 3 mL of 50:50 (v:v) hexane: ethyl acetate, eluted at 1 mL/min 
into new properly labeled disposable culture tubes.  Columns were then again washed with 3 mL 
of methanol at 1 mL/min and dried at 35 psi for a minimum of 15 min with additional time if 
columns were not fully dry.  The basic fraction was then eluted by gravity into new properly 
 
labeled disposable culture tubes with 3 mL 78:20:2 (v:v:v) methylene chloride: isopropanol: 
ammonium hydroxide.  Eluted samples were then evaporated to dryness under a gentle stream of 
nitrogen with the use of a RapidVap Vertex Drydown Evaporator (Labconco, Kansas City, 
Missouri, USA).  Samples dried at <5 psi at 40°C and checked frequently.  As soon as a tube was 
evaporated to dryness it was removed to prevent blowing away of analytes or thermal 
degradation.  Dried samples were then reconstituted in 100 µL of high purity ethyl acetate and 
transferred to a 9mm clear screw cap gas chromatograph (GC) autosampler vial with a 200 µL 
insert.  Samples were then ready for instrumental analysis. 
Column Capacity 
 Initial concerns were about how large of a sample volume would be too large and 
overload the extraction column.  Using the standard extraction method, variable sample sizes of 
25, 50, 75, and 100 mL were used to determine at what point the column was not binding to 
additional analyte.  One of the wastewater samples known to have a high level of nicotine was 
used as the sample source.  The extracted samples were then run on the GC/MS and nicotine 
peak abundances were compared.  
Solid Phase Extraction Rate 
 SPE extractions require multiple conditioning, wash, and elution steps in addition to 
sample introduction.  Working with a large sample volume of 500 mL can cause this extraction 
process to be tedious and lack efficiency.  Many SPE methods that utilize a positive pressure 
manifold recommend allowing the sample to pass through at a rate of 1 mL/min.  Conforming to 
this extraction rate would cause the entire extraction process to be upwards of ten hours prior to 
 
instrumental analysis.  A small experiment was designed to evaluate the recovery of two 
compounds, nicotine and methadone, at various extraction rates.  Samples (n=3) were all 
fortified with 1000 ng total of both analytes and extracted at rates of 1, 5, and 10 mL/min and 
their resulting recoveries were compared in order to evaluate an optimal extraction flow rate. 
Gas Chromatography-Mass Spectrometry Optimization  
Samples were to be run on a Shimadzu gas chromatograph-mass spectrometer (GC/MS) 
model GCMS-QP2020 (Shimadzu, Koyoto, Japan) optimized for the analysis of wastewater.  
Prior to sample introduction, proper autosampler vials and caps were evaluated.  Samples were 
reconstituted in 100 µL of ethyl acetate, with a low reconstitution volume it was necessary that 
the 2 mL autosampler vials be equipped with a 200 µL vial insert so the instrument autosampler 
was able to obtain a proper sampling.  Additionally, the autosampler cap was switched from 
being rubber septum lined to one lined with Teflon.  Using ethyl acetate as the reconstitution 
solvent results in stripping of the rubber septa resulting in major interference with early eluting 
compounds (Figure 2).  Switching to a Teflon lined cap negates this interference allowing for 
clearly defined peaks (Figure 3).   
Various injection volumes of 0.5, 1.0, and 2.0 µL were evaluated to determine what 
volume would best be suited for this analysis.  Since concentrations of drugs in wastewater can 
often be low, in the ng/L range, it is necessary to introduce as much sample as possible onto the 
column without negatively affecting the chromatography or the instrument.  Chromatograms 
from each 0.5, 1.0, and 2.0 µL injection volumes (Figures 4-6) were evaluated to determine if 
increasing the injection volume increased the abundance of certain compounds while 
maintaining Gaussian peak shapes and adequate compound separation.  It was determined that 
 
increasing the injection volume to 2 µL increased peak abundances while maintaining quality 
chromatography.   
Additionally, since a splitless injection was being performed at a 2 µL injection volume a 
splitless liner packed with glass wool was used in the instrument’s inlet.  The glass wool adds 
more surface area for the injected sample to spread across increasing the volatility.  To further 
increase volatility of the larger injection volume the inlet was set at 250ºC, hot enough to 
volatilize the entire sample but not so hot as to degrade analytes of interest. 
Helium was utilized as the carrier gas for GC/MS operation.  Typical flow rates when 
using helium as the carrier gas range from 1-2 mL/min.  Using a lower flow rate allows for 
analytes to interact with the column's stationary phase longer to increase separation.  A higher 
flow rate will not hurt the instrument but will decrease the sensitivity.  A 1 mL/min constant flow 
rate was used for this method.  The purge flow was determined based on what was necessary to 
clear the inlet of un-volatilized residual sample in order to prevent a secondary sampling.  A 
purge rate of 10 mL/min after one minute of sampling proved to be inadequate (Figure 7) 
allowing for dual sampling and two peaks resulting for each compound.  Increasing the purge 
flow rate to 30 mL/min after a sampling time of one minute remedied this issue (Figure 8). 
Analysis was carried out on a 30-meter 5% phenyl siloxane column with a diameter of 
0.25 mm and a film thickness of 0.25 µm.  This was chosen as this style of column has been 
shown to exhibit high quality chromatography in regards to drug analysis and offers a high 
temperature limit (400ºC).  This allowed for an oven temperature program to increase to, and be 
held at, 300ºC for an extended time with minimal column bleed.  The oven program ramp was 
from 70-300ºC at 15ºC/min to allow for sufficient analyte-stationary phase interaction without 
having the method be inefficiently long.   
 
The mass spectrometer was capable of operating in both chemical ionization (CI) and 
electron impact (EI) ionization modes, and EI was selected for this study.  The MS quadrupole 
was set to scan a range that would encompass all drugs of interest.  Drugs are small molecules 
therefore a tight scan range of 35-550 m/z could be set.  The instrument is operating in full scan 
mode with this ion range as this is to be an untargeted method for the detection of all drugs.  
Increasing the scan range can have a number of effects on the instrument.  Scanning too high of a 
m/z results in the detection of unwanted compounds and scanning too low results in many 
atmospheric interferences.  Also, the larger the scan range the slower the detector can scan this 
range and can result in decreased sensitivity.  The scan rate of the detector is equal to how fast 
the detector is able to scan the entire selected mass to charge range, or the inverse of a dwell 
time.  The dwell is the amount of scans the detector is able to perform in a single second.  Thus, 
a dwell of 20 means 20 scans per second or equal to a scan rate of 0.05 seconds.  Utilizing too 
low of a scan rate can result in missed ions or analytes.  However scanning at too high of a scan 
rate can result in poor chromatographic peak shape (Figure 9) and loss of sensitivity.  It is 
necessary to optimize the scan rate so that no analytes are missed while maintaining Gaussian 
peaks (Figure 10).  All parameters of the GC/MS need to be optimized per the analysis being 
performed in order to produce the best chromatography and detection of analytes of interest. 
Results and Discussion  
Column Capacity 
   The 25, 50, 75, and 100 mL samples used to evaluate the columns binding capacity all 
showed an increase in retention proportional to their increased sample size.  The resulting 
column capacity curve (Figure 11) demonstrated that even with the 100 mL sample the column 
 
binding did not reach its maximum capacity.  Column capacity curves rise sharply as the amount 
of analyte increases before plateauing at its maximum binding efficiency.  The experimental 
column capacity curve produced (Figure 11) shows that the binding is still rising with the 
increased sample volumes.  Therefore, it was determined that an even larger sample volume 
could be used, settling on a sample size of 500 mL.  The 500 mL influent sample volume is 
larger than that of most of the developed targeted methods that utilize sample volumes ranging 
from 5-250 mL of influent but increase to 500 mL when analyzing effluent samples.  Targeted 
liquid chromatography methods can use decreased sample volumes as they have increased 
sensitivity when operating in SRM or MRM modes and have the advantage of increased 
injection volumes.   
Solid Phase Extraction Rate 
 All 1000 ng fortified samples extracted at rates of 1, 5, and 10 mL/min and their resulting 
recoveries were compared (Figure 12) to determine an optimal extraction flow rate.  Calculated 
nanogram recovery and raw area counts for variable extraction rates were also compared (Table 
4; Table 5).  Comparing the recovery amounts of the extracted samples to that of the neat 
standard there was no significant difference between the 1, 5, and 10 mL/min extraction rates.  
Recovery of methadone in the extracted samples exceeded 100% when compared to the 
calibration curve but the standard deviation and bias are within 10% of the true value.  This 
amount of fluctuation occurs due to random and systematic errors throughout the extraction and 
instrumental analysis and therefore it is expected.  Based upon this data, future sample 
extractions could be performed at 10 mL/min increasing the extraction rate tenfold and reducing 
the overall extraction time without any loss in analyte recovery.    
 
Gas Chromatography-Mass Spectrometry  
Extracted samples were run on a Shimadzu single quadrupole gas chromatograph-mass 
spectrometer (GC/MS) model GCMS-QP2020 (Shimadzu, Koyoto, Japan) equipped with a 
Shimadzu AOC-20i autosampler utilizing the following optimized method.  Onto a wool packed 
splitless liner (Shimadzu Part#:221-48876-03), 2 µL of sample is injected onto the instrument 
installed with an Agilent J&W HP-5MS (30 m × 0.25mm, 0.25 µm) column (Agilent 
Technologies, Santa Clara, California, USA).  Utilizing helium as the carrier gas the instrument 
operated in constant flow mode at a rate of 1.0 mL/min.  The GC oven was programmed as 
follows: held at the initial temperature of 70°C for 2 min then ramped at 15°C/min to 300°C and 
held for 10 min for a total run time of 27.33 min.  The injection port, transfer line, and source 
were set at 250°C, 280°C, and 200°C respectively.    The MS operated in full scan mode, 
scanning ions from 35-550 m/z at an event time of 0.20 seconds (sec) from 3.50-27.33 minutes.  
The instrument control and data processing were operated by Shimadzu GCMSsolutions 
laboratory software. 
Relative Retention Times 
 An SPE extraction used in conjunction with a GC/MS full scan method was used in the 
effort to detect and quantify over fifty pharmaceuticals (Table 6).  To establish relative retention 
times (RRT) for each analyte, neat standards of every compound were run independently.  RRTs 
were calculated in reference to the methadone-d9 internal standard (analyte/IS) run with each 
analyte.  The resulting RRTs for each compound can be seen in Table 7.  This is necessary as 
this is an untargeted method for the analysis of drugs in wastewater and previously developed 
 
targeted methods are focused on a limited number of analytes and can optimize separation of 
these compounds whereas in an untargeted method analytes may overlap.   
Extracted Sample Analysis 
 Samples carried out through the SPE extraction were run under the developed GC/MS 
method.  Although both basic and acidic fractions were collected, acidic fractions exhibited poor 
chromatography and the acidic and neutral compounds were lost in the resulting chromatograms.  
This may be due to the acid/neutral fraction being eluted using a 50:50 (v/v) solution of hexanes 
and ethyl acetate.  The SPE column is washed with hexanes prior to this elution step in order to 
remove any bound proteins and lipids, but any that still remain will be eluted with the 50:50 
mixture along with the analytes of interest.  These excess lipids cause interference when 
analyzing the extractions on the GC/MS.  The basic fraction produced more reliable 
chromatography with few overlapping compounds (Figure 12).  Not all drugs were present and 
identifiable in the basic fraction limiting the number of analytes used for the development of 
calibration curves and quantitation.  Therefore, the final number of analytes used for quantitation 
purposes was 42.  However, due to the method being untargeted and utilizing the mass 
spectrometers full scan setting, all other analytes present in a sample will still be detected but not 
quantitated.  Identification of compounds in the calibrator mix were made based upon RRT and a 
positive library match within the Scientific Working Group for the Analysis of Seized Drugs 
(SWGDRUG) or the National Institute of Standards and Technology (NIST) libraries.  For 
compounds not in the calibration mix, identification was made solely with the use of MS 
libraries.   
Calibration Curves 
 
 Calibration curves for the 42 identifiable analytes were constructed with calibrators at 
concentrations of 0.1, 0.2, 0.4, 1.0, 2.0, 3.0, and 4.0 ng/mL (Figures 4-45).  Since the MS was 
run in scan mode and some analytes in the calibration mix overlapped with one another (Figure 
13), extracted ion chromatograms were used (Figure 14) to quantitate these compounds.  
Additionally, no background correction was performed in order to eliminate the possibility of 
removing low level analytes buried in the baseline.  Calibration curves were constructed based 
upon a single quantification ion, usually the base peak unless interference was detected.  Ions 
used for quantification are listed in Table 8.  No qualifier ions were used for identification as IDs 
were made as previously described.  Calibration curves were plotted with the concentration on 
the x-axis and an analyte/IS ration on the y-axis.  Curves were acceptable if they had a 
coefficient of determination (R2) value greater than or equal to 0.9875 and bias in the calibrators 
less ≤30%.  While SWGTOX guidelines allow for 20% bias and some laboratories use 10% bias, 
≤30% bias is acceptable for the purpose of monitoring communal drug use since a more stringent 
acceptable bias would not have a significant impact on the overall results. 
Out of 42 drug calibration curves more than 75% of the analytes ran had a passing curve 
in a single run.  Some analytes such as early eluting and late eluting compounds need refining in 
order to make curves acceptable.  Possibly increasing the calibrator concentrations of those 
analytes with failing curves have low responses even at higher concentrations so that the lower 
calibrators are better detected.  This low abundance in lower calibrators of these compounds 
results in having high bias (>30%) and reduces the curves R2 values.  For early and late eluting 
compounds the addition of more deuterated internal standards closer in retention time to these 
analytes may improve their bias.  All compounds in this method reference methadone-d9 as the 
internal standard which is located in the middle of the chromatogram.  Since the single IS is in 
 
the middle of the chromatogram it does not experience the same errors and interferences as those 
eluting much earlier or later in the chromatogram.  Adding two additional internal standards such 
as methamphetamine-d5 for use with early eluting compounds and buprenorphine-d4 for the late 
eluting compounds will aid in correcting some of the biases that occur when referencing a distant 
internal standard.     
Current methods for wastewater analysis are developed to analyze an isolated panel of 
drugs.  A majority of these utilize liquid chromatography (Table 2) in either SRM or MRM 
modes and are incapable of being utilized as a tool for untargeted monitoring of community drug 
use.  Gas chromatography methods have been developed for wastewater analysis (Bisceglia et 
al., 2010; Logarinho et al., 2016; Racamonde et al., 2012; Shao et al., 2020; Thomas et al., 2004) 
have similar issues as LC methods.  These GC methods use SIM mode to focus on a limited 
scope of analytes, potentially missing several compounds outside their detection parameters.  
González-Mariño et al. (2010) developed a GC/MS method for wastewater analysis to operate in  
scan mode.  However, the method does not use the scan mode setting to its fullest potential, 
scanning only for small ranges of ions across short time windows.  Essentially, the method is a 
modified, compound specific scan method that limits detection to a short list of stimulant and 
opioid compounds used in the calibration standards.  Even with this limited scope of analytes, 
the González-Mariño method has calibration curves from 5-500 ng/mL, which are far less 
sensitive than the 0.10-4.0 ng/mL curves developed in the method developed in this study.  
Additionally, all the GC methods found in the peer-reviewed derivative analysis, increases 
analytical cost and sample preparation time. Derivatization can increase the sensitivity of many 
metabolites but does not improve the detection of parent compounds since the derivatizing 
compounds do not react with the parent analytes.  None of the current wastewater methods found 
 
in the literature propose a true untargeted full scan method, thus, are insufficient for 
comprehensive monitoring of communal drug use.   
Conclusion 
Wastewater analysis is a proven effective way for monitoring community drug use and 
has many benefits to the public.  Monitoring public use allows for the establishment of drug 
specific education and treatment programs in the affected areas.  Focusing more on prevention 
and education versus traditional punitive methods of dealing with a drug epidemic.  Economical 
and efficient monitoring of wastewater also keeps law enforcement and medical professionals on 
top of current drug trends allowing for the proper treatment of overdose victims.  With the 
current state of the drug epidemic the current method of self-reporting surveys, overdose 
monitoring, and arrest records are longer viable options.  Waiting 2-3 years for biased data is too 
long to wait for outdated unreliable data.  With the emerging drug trends of new novel 
psychoactive substances being produced faster than forensic scientists can keep up, an untargeted 
GC screen for processing wastewater can help scientists better keep up with those who need 
help. 
This research has demonstrated that it is possible to create a reliable full scan screening 
method via GC/MS for the detection and quantitation of pharmaceuticals.  Additionally, this 
method uses an increased extraction rate which lends itself to more efficiently extracting large 
samples.  It has greater efficiency then other GC/MS methods that require derivatization and 
many of those focus solely on a smaller panel of drugs.  Gas chromatography and its methods are 
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Table 1: Solid phase extraction schemes for the analysis of influent wastewater.  The location 
under author name is the location the analysis was conducted, which may be different from the 
































250 mL Phenomenex Strata-X Column (6 mL/500 mg): 
(Condition: 6 mL MeOH, 6 mL DI Water) 
(Sample: Filtered/Unbuffered @ 10 mL/min) 
(Wash: 6 mL DI Water)  
(Elution: 6 mL MeOH) 






























































































50 mL Phenomenex Strata-XC Column (6 mL/250 mg): 
(Condition: 6 mL MeOH, 6 mL Acidified DI 
Water pH 2.5) 
(Sample: Filtered/Buffered pH 2.5 by Gravity) 
(Wash: 3 mL Acidified DI Water) 





























































100 mL Waters Oasis MCX Column (3 mL/60 mg): 
(Condition: 2 mL MeOH, 3 mL Acidified DI 
Water pH 2) 
(Sample: Filtered/Buffered pH 2 @ 5 mL/min) 
(Wash: 2 mL 2% Formic acid, 3 mL MeOH) 







































50-500 mL Waters Oasis Max Column (150 mg): 
(Condition: MeOH, DI Water) 
(Sample: Filtered/Unbuffered @ 5 mL/min) 









































N/A 50 mL Waters Oasis HLB Column (6 mL/150 mg): 
(Condition: 8 mL MeOH, 8 mL DI Water) 
(Sample: Filtered/Unbuffered) 
(Wash: 4 mL DI Water) 
(Elution: 8 mL MeOH) 




















































5 mL Waters Oasis HLB Column (3 mL/60 mg): 
(Condition: 6 mL MeOH, 6 mL DI Water) 
(Sample: Unfiltered/Unbuffered) 
(Wash: 50 mL DI Water) 
(Elution: 1 mL MeOH) 
 























N/A 200 mL Waters Oasis HLB Column (6 mL/500 mg): 
(Condition: 10 mL MeOH, 10 mL DI Water) 
(Sample: Filtered/Unbuffered @ 2 mL/min) 
(Wash: 10 mL DI Water) 
(Elution: 10 mL MeOH) 
González-





























































Waters Oasis MCX Column (6 mL/500 mg): 
(Condition: 2 mL 95:5 MeOH:NH4OH, 2 mL 
Acidified DI Water pH 4.5) 
(Sample: Filtered/Buffered pH 4.5 @ 10 mL/min) 
(Wash: 10 mL DI Water) 
(Elution: (Acidic) 2 mL MeOH, (Basic) 4 mL 
95:5 MeOH:NH4OH)  
Gul et al. 
(2016)a 





































15 mL Phenomenex Strata Screen-C (3 mL/150 mg): 
(Condition: 2 mL MeOH, 2 mL DI Water) 
(Sample: Filtered/Unbuffered) 
(Wash: 9 mL 0.1N HCl, 6 mL MeOH) 
































Mallinckrodt Baker RP-C18 (6 mL/500 mg): 
(Condition: 4 mL 80:20 MeOH:Acetone, 4 mL 
MeOH, 4 mL DI Water) 
(Sample: Filtered/Unbuffered @ 15 mL/min) 
(Wash: 4 mL DI Water) 
(Elution: 4 mL 80:20 MeOH:Acetone) 






















50 mL Waters Oasis MCX Column (3 mL/60 mg): 
(Condition: 6 mL MeOH, 4 mL DI Water, 4 mL 
Acidified DI Water pH 2) 
(Sample: Filtered/Buffered pH 2 @ 2.5 mL/min) 
(Wash: 3 mL DI Water) 
(Elution: 2 mL MeOH, 2 mL 95:5 
MeOH:NH4OH)  






85-105 50 mL Waters Oasis MCX Column (3 mL/60 mg): 
(Condition: MeOH, DI Water, Acidified DI Water 
pH 2)(Sample: Filtered/Unbuffered) 
(Wash: 4 mL DI Water) 
(Elution: 4 mL 95:5 MeOH:NH3)  





































300 mL 3M Empore 47mm Cation Disk: 
(Condition: 8 mL MeOH, 8 mL DI Water, 8 mL 
acidified DI Water pH 3) 
(Sample: Filtered/Buffered pH 3 by Gravity) 
(Wash: 10 mL DI Water, 10 mL 90:10 DI 
Water:MeOH) 






















50 mL Phenomenex Strata-X Column (250 mg): 
(Condition: 2 mL MeOH, 2 mL Acidified DI 
Water pH 5) 
(Sample: Filtered/Unbuffered) 
(Wash: 2 mL 0.1N HCl, 2 mL 0.1N HCl in MeOH 
) 
(Elution: 6 mL MeOH) 
(Elution: 2 mL 95:5 MeOH:NH3) 
Mosekiemang 
















N/A 50 mL Phenomenex Strata SDB-L Column (6 mL/200 
mg): 
(Condition: 4 mL CAN, 4 mL MeOH, 4 mL DI 
Water pH 7) 
(Sample: Filtered/Buffered pH 7 @ 1 mL/min) 
(Elution: 4 mL 49:49:2 MeOH:DCM:Formic acid) 











































Waters Oasis HLB Column (6 mL/500 mg): 
(Condition: 10 mL MeOH, 10 mL DI Water) 
(Sample: Filtered/Unbuffered @ 2 mL/min) 
(Wash: 10 mL DI Water) 
(Elution: 10 mL MeOH) 
 
Salgueiro-






















































N/A 50 mL Waters Oasis HLB Column (3 mL/60 mg): 
(Condition: 6 mL MeOH, 3 mL DI Water) 
(Sample: Filtered/Buffered pH 7 @ 5 mL/min) 
(Elution: 4 mL MeOH) 
 
Waters Oasis MCX (6 mL/150 mg) 
(Condition: 10 mL MeOH, 5 mL DI Water, 5 mL 
Acidified DI Water pH 2) 
(Sample: Filtered/Buffered pH 2 @ 5 mL/min) 
(Elution: 2 mL 98:2 MeOH:NH3) 










60 mL Waters Oasis MCX Column (3 mL/60 mg): 
(Condition: 6 mL MeOH, 4 mL DI Water, 4 mL 
Acidified DI Water pH 2) 
(Sample: Unfiltered/Buffered pH 2) 
(Elution: 4 mL 96:4 MeOH:NH3)  
 
Stamper et al. 
(2016) 






































30 mL Phenomenex Strata Screen-C (3 mL/150 mg): 
(Condition: 2 mL MeOH, 2 mL DI Water) 
(Sample: Filtered/Unbuffered) 
(Wash: 9 mL 0.1N HCl, 6 mL MeOH) 
(Elution: 2 mL 99:1 MeOH:NH3) 





























100 mL Waters Oasis HLB Column (6 mL/200 mg): 
(Condition: 4 mL MeOH, 4 mL DI Water) 
(Sample: Unfiltered/Unbuffered @ 10 mL/min) 
(Wash: 20 mL DI Water) 
(Elution: 4 mL MeOH) 





























Waters Oasis MCX Column: 
(Condition: 6 mL Acetone, 6 mL MeOH, 6 mL 
Acidified DI Water pH 2.5 @ 1 ml/min) 
(Sample: Filtered/Buffered pH 2.5) 
(Elution: 9 mL 95:5 MeOH:NH4OH)  
N/A= Not available or not given, MeOH= Methanol, DCM= Dichloromethane 
2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine(EDDP); Lysergic acid diethylamide (LSD); 3,4-Methylenedioxyamphetamine(MDA); 3,4-
Methylenedioxy-N-ethylamphetamine(MDEA); 3,4-Methylenedioxymethamphetamine(MDMA); Methylenedioxypyrovalerone (MDPV); 
Phencyclidine (PCP); para-Methoxyamphetamine (PMA); para-Methoxymethamphetamine (PMMA) 
 
  
Table 2: Liquid Chromatography-Mass Spectrometry methods for the analysis of 
pharmaceuticals in wastewater.  The location under author name is the location the analysis was 
conducted, which may be different from the sample collection location. 
Liquid Chromatography Mass Spectrometer 















Phenomenex Kinetex C18 
(50 mm×2.10 mm, 1.7 μm) 
Mobile A: 0.1% Formic Acid 
in Water 
Mobile B: 0.1% Formic Acid 
in Methanol 
Equilibration: 15 min 
Gradient: 12 min 10%(5)-95%(13) @ 
30°C 
Flow: 0.20 mL/min 
ESI (+) Agilent 6410 QqQ-MS/MS 
 
AB Sciex Triple TOF 6400 
 
SRM 







Phenomenex Kinetex PFP 
(50 mm×2.10 mm, 1.7 μm) 
Mobile A: 0.05% Formic 
Acid in Water 
Mobile B: 0.05% Formic 
Acid in Methanol 
Positive Mode 
Equilibration: 16 min 
Gradient: 20 min 2%(3)-100%(20) @ 
25°C 
Purge: 26 min 
Flow: 0.10 mL/min 
 
Negative Mode 
Equilibration: 5 min 
Gradient: 20 min 2%(3)-100%(20) @ 
25°C 
Purge: 7 min 
Flow: 0.10 mL/min 
ESI (+/-) Thermo TSQ QqQ-MS/MS SRM 







Phenomenex Kinetex C18 
(100 mm×2.10 mm, 2.6 
μm) 
Mobile A: 0.5% Acetic Acid 
in Water 
Mobile B: Acetonitrile 
Equilibration: 9 min 
Gradient: 5 min 0%(5)-40% @ 30°C 
1 min 40%-100% @ 30°C 
Purge: 1 min 
Flow: 0.35 mL/min 











(100 mm×2.1 mm, 3.5 μm) 
Mobile A: 1 mM ammonium 
acetate in Water 
Mobile B: 1 mM ammonium 
acetate in Methanol 
Equilibration: 7 min 
Gradient: 6 min 15%(2)-40% @ 35°C 
6 min 40%-70% @ 35°C 
3 min 70%-100% @ 35°C 
Purge: 3 min 
Flow: 0.15 mL/min 















(100 mm×2.1 mm, 2.6 μm) 
Mobile A: 0.04% Formic 
Acid in Water 
Mobile B: 0.04% Formic 
Acid in 80:20 ACN:Water 
Equilibration: 3.5 min 
Gradient: 18 min 2%(2)-40% @ ?°C 
7 min 40%-90%(4) @ ?°C 
Purge: 0.5 min 
Flow: 0.40 mL/min 
ESI (+) Agilent 6530 QTOF-MS 
 
Thermo LTQ-FT Orbitrap 
Scan 









Waters Acquity UPLC 
BEH C18 
(50 mm×2.10 mm, 1.7 μm) 
Mobile A: 0.1% Formic Acid 
in Water 
Mobile B: 0.1% Formic Acid 
in Methanol 
Equilibration: 5.5 min 
Gradient: 2 min 10%-60% @ 40°C 
0.5 min 60%-90%(1) @ 40°C 
Purge: 3.6 min 
Flow: 0.30 mL/min 
ESI (+) Waters Xevo TSQ 
QqQ-MS/MS 
SRM 







Waters Xbridge Phenyl 
(150 mm×3 mm, 3.5 μm)  
Mobile A: ACN 
Mobile B: 5 mM Ammonium 
Formate in Water pH 4 
Equilibration: 5.5 min 
Gradient: 19 min 98(3)%-10%(2) @ 
?°C 
Purge: 0.5 min 
Flow: 0.40 mL/min 













Nucleosil 100-3 C18 HD 
(125 mm×2 mm, 3 μm) 
Mobile A: 5 mM ammonium 
acetate in Water pH 8.5 
Mobile B: 5 mM ammonium 
acetate in Methanol pH 4.5 
Equilibration: 10 min 
Gradient: 24.8 min 2%(0.2)-50% @ 
40°C 
4 min 50%-100% @ 40°C 
Purge: 1 min 
Flow: 0.20 mL/min 
ESI (+) Agilent 6520 QTOF-MS SRM 
Gul et al. 
(2016)a  
Gul et al. 
(2016)b 
Stamper et al. 
(2016) 









Hydro-RP column  
(150mm×3.0 mm; 4 μm) 
Mobile A: 0.1% Formic Acid 
in Water 
Mobile B: 0.1% Formic Acid 
in ACN 
Equilibration: 4.5 min 
Gradient: 1 min 2%(2)-20% @ 30°C 
5 min 20%-60% @ 30°C 
2 min 60%-80% @ 30°C 
Purge: 0.5 min 
Flow: 0.65 mL/min 











Waters Acquity UPLC 
BEH C18 
(50 mm×2.10 mm, 1.7 μm) 
Mobile A: 0.2% Acetic Acid 
in Water 
Mobile B: 0.2% Acetic Acid 
in Methanol 
Equilibration: 3 min 
Gradient: 5.4 min 30%(0.6)-90%(2) @ 
40°C 
Flow: 0.20 mL/min 













Phenomenex Luna HILIC 
(150 mm×3 mm, 5 μm) 
Mobile A: 5 mM Ammonium 
Acetate in Water 
Mobile B: ACN 
Equilibration: 4.3 min 
Gradient: 4.5 min 95%(0.5)-90% @ ?°C 
7.5 min 90%-70%(0.1) @ ?°C 
2 min 70%-30% @ ?°C 
Purge: 0.1 min 
Flow: 0.40 mL/min 
ESI (+) Agilent 6410 QqQ-MS/MS MR
M 







Phenomenex Luna HILIC 
(150 mm×3 mm, 5 μm) 
Mobile A: 5 mM Ammonium 
Acetate in Water 
Mobile B: ACN 
? 
Flow: 0.60 mL/min 











Waters Acquity BEH C18 
(150 mm×2.10 mm, 1.7 
μm) 
Mobile A: 0.1% Formic Acid 
in 10 mM Ammonium 
Acetate 
Mobile B: ACN 
Gradient: 10 min 20%(5)-60% @ ?°C 
Purge: 5 min 
Flow: 0.30 mL/min 













Waters Acquity HSS T3 
(150 mm×2.10 mm, 1.8 
μm) 
Mobile A: 0.1% Formic Acid 
in Water 
Mobile B: ACN 
Equilibration: 3 min 
Gradient: 8 min 2%(0.2)-98%(0.5) @ 
35°C 
Purge: 0.5 min 
Flow: 0.30 mL/min 











Waters Xbridge Phenyl 
(150 mm×3 mm, 3.5 μm)  
Mobile A: ACN 
Mobile B: 5 mM Ammonium 
Formate Buffer pH 4 
Equilibration: 5.5 min 
Gradient: 19 min 98%(3)-10% @ ?°C 
Purge: 0.5 min 
Flow: 0.40 mL/min 











Waters Xbridge C18 
(100 mm×2.1 mm, 3.5 μm)  
Mobile A: 0.1% Formic Acid 
in Water 
Mobile B: ACN 
Equilibration: 6 min 
Gradient: 20 min 10%-60% @ 30°C 
5 min 60%-99%(5) @ 30°C 
Purge: 1 min 
Flow: 0.20 mL/min 
ESI (+) Thermo Q-Exactive Hybrid 
Q-Orbitrap 
Scan 









(100 mm×2 mm, 3 μm) 
Mobile A: 10 mM 
Ammonium Acetate Buffer 
pH 3.2  
Mobile B: 0.1% Formic Acid 
in Methanol 
Equilibration: 10 min 
Gradient: 0 min 15%-95%(8) @ 40°C 
Purge: 2 min 
Flow: 0.30 mL/min 
ESI (+) AB Sciex 4000 QTrap SRM 
  
 
Table 3: Gas Chromatography Mass Spectrometry methods for the analysis of pharmaceuticals in 
wastewater.  The location under author name is the location the analysis was conducted, which 
may be different from the sample collection location. 
Gas Chromatograph Mass Spectrometer   










8000Top GC  




? J&W Scientific DB-5MS 
(30 m × 0.25mm, 0.25 µm) 
















Helium @ 1.3 
mL/min 
J&W Scientific HP-5MS 
(30 m × 0.25mm, 0.25 µm) 
90°C(1)-130°C @ 25°C/min - 
280°C(5) @ 4°C/min 
Varian Saturn 













J&W Scientific HP-5MS 
(30 m × 0.25mm, 0.25 µm) 

















Helium @ 1.0 
mL/min 
J&W Scientific HP-5MS 
(30 m × 0.25mm, 0.25 µm) 
90°C(3)-170°C @ 25°C/min - 











1 µL Splitless @ 
230°C 
Derivatized: TFA 
? J&W Scientific HP-1 
(30 m × 0.25mm, 0.25 µm) 












? Varian Factor Four-5MS 
(30 m × 0.25mm, 0.25 µm) 




























































































































































































































































































































Figure 8: Sample chromatograph with purge flow rate of 30 mL/min after 1 min sampling time. 
 
 














Figure 10: Sample chromatograph utilizing a scan rate of 0.20 seconds  
 
Figure 11: Percent recovery comparison of variable extraction rates using methadone and 
nicotine fortified at 1000 ng total per sample. (n=3) 
 
Table 4: Calculated value of 1000 ng total fortified samples from variable extraction rates (n=3). 
Sample Nicotine (ng) Nicotine (STD) Methadone (ng) Methadone (STD) 
1 mL/min 981.8 24.4 1029.8 6.5 
5 mL/min 979.3 17.2 1039.2 23.6 
10 mL/min 1017.0 32.1 1084.5 16.1 
Neat 890.3 3.7 1062.0 62.0 
 
Table 5: Raw area counts of 1000 ng total fortified samples from variable extraction rates (n=3). 
Sample Nicotine 133 m/z Nicotine (STD) Methadone 72 m/z Methadone (STD) 
1 mL/min 159647.0 21609.1 2399916.7 286448.7 
5 mL/min 158923.3 18953.3 2667522.7 79342.9 
10 mL/min 158050.3 30493.8 2554780.3 234138.9 


























Table 6: Compounds included in method analysis  
Compound List 




































































18 Diazepam 36 Naloxone   
 
 




IS Retention Time 
(min) 
Relative Retention Time 
Valproic Acid  5.543 13.853 0.400 
Amphetamine 5.970 13.853 0.431 
Methamphetamine 6.643 13.853 0.480 
Salicylic Acid 7.197 13.853 0.520 
n-Propylamphetamine (IS) 7.630 13.850 0.551 
Methcathinone 7.687 13.853 0.555 
Nicotine 7.740 13.853 0.559 
n-ethcathinone 8.203 13.853 0.592 
MDMA 9.403 13.853 0.679 
Gabapentin 9.703 13.850 0.701 
Acetaminophen 10.563 13.850 0.763 
Meprobamate 11.490 13.850 0.830 
Norketamine 11.727 13.853 0.847 
Norfluoxetine 11.807 13.853 0.852 
Fluoxetine 11.943 13.850 0.862 
Ketamine 11.970 13.850 0.864 
Diphenhydramine 12.030 13.850 0.869 
Carisoprodol 12.053 13.850 0.870 
Norfentanyl 12.693 13.853 0.916 
EDDP 13.203 13.850 0.953 
Methadone-d9 (IS) 13.850 13.850 1.000 
Dextromethorphan 13.863 13.853 1.001 
Methadone 13.894 13.850 1.003 
Amitriptyline 14.207 13.850 1.026 
Cocaine 14.267 13.850 1.030 
Nortriptyline 14.323 13.853 1.034 
Cyclobenzaprine 14.483 13.850 1.046 
Cocaethylene 14.593 13.850 1.054 
Promethazine 14.733 13.853 1.064 
Codeine 15.370 13.850 1.110 
Citalopram 15.413 13.850 1.113 
n-desmethylcitalopram 15.570 13.850 1.124 
Morphine 15.650 13.853 1.130 
Diazepam 15.673 13.850 1.132 
Hydrocodone 15.747 13.850 1.137 
THCA-A 15.787 13.853 1.140 
THC 15.790 13.853 1.140 
Hydromorphone 15.820 13.850 1.142 
Nordiazepam 16.040 13.853 1.158 
6-monoacetylmorphine 16.127 13.850 1.164 
Oxycodone 16.190 13.853 1.169 
Oxymorphone 16.273 13.853 1.175 
Paroxetine 16.367 13.853 1.181 
Benzoylecgonine 16.437 13.850 1.187 
Midazolam 16.500 13.853 1.191 
Naloxone 16.980 13.853 1.226 
Fentanyl 17.107 13.850 1.235 
Zolpidem 17.563 13.853 1.268 
7-aminoclonazepam 17.800 13.853 1.285 
Clonazepam 17.843 13.850 1.288 
Alprazolam 18.443 13.850 1.332 
α-Hydroxyalprazolam 18.987 13.850 1.371 
Norbuprenorphine 20.410 13.853 1.473 
Trazodone 21.680 13.853 1.565 
Buprenorphine 22.517 13.850 1.626 






















































































































































































































































































Figure 14: Calibrator extracted ion chromatogram (44, 58, and 180 m/z) with overlapping analyte 













































Table 8: Quantification ions used for calibration curve construction for each analyte 
Drug Name Quant Ion (m/z) Drug Name 
Quant Ion 
(m/z) 
Amphetamine 44 Citalopram 58 
Methamphetamine 58 Desmethylcitalopram 44 
Methcathinone 58 Morphine 285 
Nicotine 84 Diazepam 256 
n-Ethcathinone 72 Hydrocodone 299 
MDMA 58 Hydromorphone 285 
Norketamine 166 Nordiazepam 242 
Ketamine 180 6-MAM 327 
Fluoxetine 44 Oxycodone 315 
Diphenhydramine 58 Oxymorphone 301 
Norfentanyl 83 Paroxetine 44 
EDDP 277 Benzoylecgonine 124 
Dextromethorphan 59 Midazolam 310 
Methadone-D9 78 Naloxone 327 
Methadone 72 Fentanyl 245 
Amitriptyline 58 Zolpidem 235 
Cocaine 82 7-aminoclonazepam 285 
Nortriptyline 44 Alprazolam 279 
Cyclobenzaprine 58 Norbuprenorphine 338 
Cocaethylene 82 Trazodone 205 
Promethazine 72 Buprenorphine 378 
Codeine 299   
 
 
Figure 15: Amphetamine calibration curve run 03/16/2020. R2= 0.9963 
 
Table 9: Bias for amphetamine calibration curve run 03/16/2020.  
Amphetamine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.19 94.1 
0.20 0.24 18.4 
0.40 0.31 -23.2 
1.00 0.94 -6.4 
2.00 1.94 -3.2 
3.00 3.15 4.9 






























Figure 16: Methamphetamine calibration curve run 03/16/2020. R2= 0.9914 
 
Table 10: Bias for methamphetamine calibration curve run 03/16/2020.  
Methamphetamine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.13 29.1 
0.20 0.26 30.0 
0.40 0.29 -27.3 
1.00 1.02 2.5 
2.00 1.86 -7.1 
3.00 3.26 8.7 





Figure 17: Methcathinone calibration curve run 03/16/2020. R2= 0.9801 
 
Table 11: Bias for methcathinone calibration curve run 03/16/2020.  
Methcathinone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 -0.10 -201.7 
0.20 0.21 5.8 
0.40 0.41 1.5 
1.00 1.32 31.7 
2.00 2.06 2.8 
3.00 2.66 -11.3 






Figure 18: Nicotine calibration curve run 03/16/2020. R2= 0.9780 
 
Table 11: Bias for nicotine calibration curve run 03/16/2020. 
Nicotine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.27 168.9 
0.20 0.38 92.1 
0.40 0.41 2.2 
1.00 0.76 -23.5 
2.00 1.60 -19.8 
3.00 3.11 3.6 




Figure 19: Ethcathinone calibration curve run 03/16/2020. R2= 0.9805 
 
Table 12: Bias for ethcathinone calibration curve run 03/16/2020. 
Ethcathinone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 -0.04 -138.1 
0.20 0.18 -11.9 
0.40 0.49 22.5 
1.00 1.25 24.9 
2.00 1.96 -1.9 
3.00 2.63 -12.2 





Figure 20: 3,4-methylenedioxymethamphetamine calibration curve run 03/16/2020. R2= 0.9838 
 
Table 13: Bias for 3,4-methylenedioxymethamphetamine calibration curve run 03/16/2020. 
MDMA 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.06 -35.3 
0.20 0.17 -17.1 
0.40 0.41 2.0 
1.00 0.95 -5.1 
2.00 2.18 8.8 
3.00 3.86 28.8 
























Figure 21: Norketamine calibration curve run 03/16/2020. R2= 0.9955 
 
Table 14: Bias for norketamine calibration curve run 03/16/2020. 
Norketamine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.08 -17.7 
0.20 0.24 19.9 
0.40 0.42 5.3 
1.00 1.06 6.4 
2.00 1.91 -4.7 
3.00 2.84 -5.3 






Figure 22: Ketamine calibration curve run 03/16/2020. R2= 0.9952 
 
Table 14: Bias for ketamine calibration curve run 03/16/2020. 
Ketamine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.07 -27.9 
0.20 0.21 3.2 
0.40 0.37 -6.9 
1.00 1.02 2.0 
2.00 1.96 -2.2 
3.00 3.21 7.0 






Figure 23: Fluoxetine calibration curve run 03/16/2020. R2= 0.9941 
 
Table 15: Bias for fluoxetine calibration curve run 03/16/2020. 
Fluoxetine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.14 39.0 
0.20 0.23 15.8 
0.40 0.42 6.2 
1.00 0.95 -5.3 
2.00 1.80 -9.8 
3.00 3.19 6.4 






















Figure 24: Diphenhydramine calibration curve run 03/16/2020. R2= 0.9999 
 
Table 16: Bias for diphenhydramine calibration curve run 03/16/2020. 
Diphenhydramine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.08 -23.9 
0.20 0.19 -3.3 
0.40 0.40 1.1 
1.00 1.01 1.5 
2.00 2.03 1.5 
3.00 3.00 -0.1 




Figure 25: Norfentanyl calibration curve run 03/16/2020. R2= 0.9952 
 
Table 17: Bias for norfentanyl calibration curve run 03/16/2020. 
Norfentanyl 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.1 0.18 84.9 
0.2 0.19 -3.1 
0.4 0.39 -3.3 
1 0.81 -19.2 
2 2.13 6.6 
3 3.04 1.4 






Figure 26: EDDP calibration curve run 03/16/2020. R2= 0.9984 
 
Table 18: Bias for EDDP calibration curve run 03/16/2020. 
EDDP 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.09 -7.0 
0.20 0.18 -10.0 
0.40 0.41 2.7 
1.00 0.94 -5.7 
2.00 2.09 4.3 
3.00 3.07 2.3 






Figure 27: Dextromethorphan calibration curve run 03/16/2020. R2= 0.9996 
 
Table 19: Bias for dextromethorphan calibration curve run 03/16/2020. 
Dextromethorphan 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.08 -19.9 
0.20 0.18 -8.2 
0.40 0.46 15.5 
1.00 0.97 -2.6 
2.00 2.01 0.4 
3.00 2.98 -0.7 






Figure 28: Methadone calibration curve run 03/16/2020. R2= 0.9993 
 
Table 20: Bias for methadone calibration curve run 03/16/2020. 
Methadone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.06 -39.2 
0.20 0.18 -9.5 
0.40 0.40 1.1 
1.00 1.03 3.2 
2.00 2.03 1.6 
3.00 3.05 1.6 






Figure 29: Amitriptyline calibration curve run 03/16/2020. R2= 0.9995 
 
Table 21: Bias for amitriptyline calibration curve run 03/16/2020. 
Amitriptyline 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.09 -9.9 
0.20 0.20 -2.2 
0.40 0.40 -1.1 
1.00 0.98 -1.6 
2.00 2.03 1.7 
3.00 3.05 1.7 






Figure 30: Cocaine calibration curve run 03/16/2020. R2= 0.9951 
 
Table 22: Bias for cocaine calibration curve run 03/16/2020. 
Cocaine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.14 37.5 
0.20 0.25 23.9 
0.40 0.27 -33.4 
1.00 1.01 1.0 
2.00 1.97 -1.4 
3.00 3.18 6.0 





Figure 31: Nortriptyline calibration curve run 03/16/2020. R2= 0.9990 
 
Table 23: Bias for nortriptyline calibration curve run 03/16/2020. 
Nortriptyline 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.14 38.4 
0.20 0.22 10.7 
0.40 0.43 6.7 
1.00 0.91 -8.6 
2.00 1.95 -2.6 
3.00 3.04 1.2 






Figure 32: Cyclobenzaprine calibration curve run 03/16/2020. R2= 0.9992 
 
Table 24: Bias for cyclobenzaprine calibration curve run 03/16/2020. 
Cyclobenzaprine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.10 -3.9 
0.20 0.20 1.2 
0.40 0.40 0.5 
1.00 0.97 -3.5 
2.00 2.01 0.6 
3.00 3.08 2.7 





Figure 33: Cocaethylene calibration curve run 03/16/2020. R2= 0.9999 
 
Table 25: Bias for cocaethylene calibration curve run 03/16/2020. 
Cocaethylene 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.11 8.5 
0.20 0.21 6.2 
0.40 0.40 0.7 
1.00 0.98 -2.5 
2.00 2.00 0.0 
3.00 2.98 -0.7 






Figure 34: Promethazine calibration curve run 03/16/2020. R2= 0.9980 
 
Table 26: Bias for promethazine calibration curve run 03/16/2020. 
Promethazine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.13 31.9 
0.20 0.22 9.3 
0.40 0.42 5.4 
1.00 0.95 -4.7 
2.00 1.99 -0.4 
3.00 2.88 -3.9 





Figure 35: Codeine calibration curve run 03/16/2020. R2= 0.9985 
 
Table 27: Bias for codeine calibration curve run 03/16/2020. 
Codeine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.18 77.3 
0.20 0.23 12.7 
0.40 0.39 -2.0 
1.00 0.92 -7.9 
2.00 1.96 -2.2 
3.00 2.96 -1.2 






Figure 36: Citalopram calibration curve run 03/16/2020. R2= 0.9993 
 
Table 28: Bias for citalopram calibration curve run 03/16/2020. 
Citalopram 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.11 10.6 
0.20 0.17 -14.2 
0.40 0.42 3.8 
1.00 0.99 -1.5 
2.00 1.99 -0.5 
3.00 3.08 2.5 





Figure 37: Desmethylcitalopram calibration curve run 03/16/2020. R2= 0.9921 
 
Table 29: Bias for desmethylcitalopram calibration curve run 03/16/2020. 
Desmethylcitalopram 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.26 160.3 
0.20 0.27 34.1 
0.40 0.28 -29.9 
1.00 0.91 -9.0 
2.00 1.83 -8.7 
3.00 3.17 5.5 






Figure 28: Morphine calibration curve run 03/16/2020. R2= 0.9990 
 
Table 30: Bias for morphine calibration curve run 03/16/2020. 
Morphine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.09 -11.3 
0.20 0.21 5.4 
0.40 0.37 -6.7 
1.00 1.02 2.1 
2.00 2.06 3.1 
3.00 2.91 -2.9 





Figure 39: Diazepam calibration curve run 03/16/2020. R2= 0.9988 
 
Table 31: Bias for diazepam calibration curve run 03/16/2020. 
Diazepam 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.14 39.1 
0.20 0.22 10.6 
0.40 0.40 0.7 
1.00 0.98 -2.4 
2.00 1.95 -2.6 
3.00 2.93 -2.2 






Figure 40: Hydrocodone calibration (3.0 ng/mL point dropped due to being an outlier) curve run 
03/16/2020. R2= 0.9991 
 
Table 32: Bias for hydrocodone calibration curve run 03/16/2020. 
Hydrocodone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.09 -11.2 
0.20 0.20 -2.2 
0.40 0.41 3.5 
1.00 0.95 -4.7 
2.00 2.08 4.1 
3.00 1.99 -33.5 




Figure 41: Hydromorphone calibration (3.0 ng/mL point dropped due to being an outlier) curve 
run 03/16/2020. R2= 0.9914 
 
Table 33: Bias for hydromorphone calibration curve run 03/16/2020. 
Hydromorphone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.11 11.0 
0.20 0.21 6.5 
0.40 0.43 8.6 
1.00 1.12 12.0 
2.00 1.74 -13.1 
3.00 2.03 -32.4 





Figure 42: Nordiazepam calibration curve run 03/16/2020. R2= 0.9938 
 
Table 34: Bias for nordiazepam calibration curve run 03/16/2020. 
Nordiazepam 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.16 60.4 
0.20 0.23 13.0 
0.40 0.36 -9.8 
1.00 0.94 -5.7 
2.00 1.87 -6.4 
3.00 3.23 7.6 





Figure 43: 6-monoacetylmorphine calibration curve run 03/16/2020. R2= 0.9858 
 
Table 35: Bias for 6-monoacetylmorphine calibration curve run 03/16/2020. 
6-monoacetylmorphine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.22 116.5 
0.20 0.33 65.2 
0.40 0.42 5.8 
1.00 0.88 -11.8 
2.00 1.65 -17.6 
3.00 3.04 1.2 






Figure 44: Oxycodone calibration curve run 03/16/2020. R2= 0.9696 
 
Table 36: Bias for oxycodone calibration curve run 03/16/2020. 
Oxycodone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 -0.03 -131.9 
0.20 0.15 -22.6 
0.40 0.28 -29.0 
1.00 1.31 31.3 
2.00 2.19 9.7 
3.00 2.79 -6.9 




Figure 45: Oxymorphone calibration curve run 03/16/2020. R2= 0.9522 
 
Table 37: Bias for oxymorphone calibration curve run 03/16/2020. 
Oxymorphone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 -0.01 -110.3 
0.20 0.25 24.4 
0.40 0.26 -33.9 
1.00 1.53 53.0 
2.00 1.43 -28.5 
3.00 3.24 8.0 






Figure 46: Paroxetine calibration curve run 03/16/2020. R2= 0.9796 
 
Table 38: Bias for paroxetine calibration curve run 03/16/2020. 
Paroxetine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.16 58.7 
0.20 0.30 48.6 
0.40 0.49 22.4 
1.00 0.72 -28.1 
2.00 1.87 -6.4 
3.00 3.15 5.1 





Figure 47: Benzoylecgonine calibration (3.0 ng/mL point dropped due to being an outlier) curve 
run 03/16/2020. R2= 0.9705 
 
Table 39: Bias for benzoylecgonine calibration curve run 03/16/2020. 
Benzoylecgonine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.18 82.8 
0.20 0.38 92.1 
0.40 0.39 -1.4 
1.00 0.49 -50.9 
2.00 2.21 10.7 
3.00 6.06 102.1 





























Figure 48: Midazolam calibration curve run 03/16/2020. R2= 0.9986 
 
Table 40: Bias for midazolam calibration curve run 03/16/2020. 
Midazolam 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.13 25.5 
0.20 0.22 10.8 
0.40 0.34 -14.8 
1.00 0.96 -3.6 
2.00 2.02 1.2 
3.00 3.09 3.0 





Figure 49: Naloxone calibration run 03/16/2020. R2= 0.9698 
 
Table 41: Bias for naloxone calibration curve run 03/16/2020. 
Naloxone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.03 -74.9 
0.20 0.17 -13.5 
0.40 0.33 -18.4 
1.00 1.48 47.7 
2.00 1.57 -21.4 
3.00 3.08 2.7 























Figure 50: Fentanyl calibration curve run 03/16/2020. R2= 0.9994 
 
Table 42: Bias for fentanyl calibration curve run 03/16/2020. 
Fentanyl 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.13 30.9 
0.20 0.22 9.0 
0.40 0.40 0.8 
1.00 0.97 -3.5 
2.00 1.94 -3.2 
3.00 3.03 1.1 





Figure 51: Zolpidem calibration curve run 03/16/2020. R2= 0.9969 
 
Table 43: Bias for zolpidem calibration curve run 03/16/2020. 
Zolpidem 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.18 80.2 
0.20 0.27 36.5 
0.40 0.35 -12.0 
1.00 0.93 -7.1 
2.00 1.86 -6.8 
3.00 3.07 2.2 






Figure 52: 7-aminoclonazepam calibration curve run 03/16/2020. R2= 0.9731 
 
Table 44: Bias for 7-aminoclonazepam calibration curve run 03/16/2020. 
7-aminoclonazepam 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.35 247.5 
0.20 0.35 75.2 
0.40 0.35 -12.4 
1.00 0.61 -39.3 
2.00 2.04 2.2 
3.00 2.74 -8.7 





Figure 53: Alprazolam calibration curve run 03/16/2020. R2= 0.9973 
 
Table 45: Bias for alprazolam calibration curve run 03/16/2020. 
Alprazolam 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.18 80.1 
0.20 0.27 35.1 
0.40 0.37 -6.3 
1.00 0.90 -9.9 
2.00 1.92 -4.1 
3.00 2.97 -1.0 






Figure 54: Norbuprenorphine calibration curve run 03/16/2020. R2= 0.9685 
 
Table 46: Bias for norbuprenorphine calibration curve run 03/16/2020. 
Norbuprenorphine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.1 0.36 260.5 
0.2 0.36 80.9 
0.4 0.39 -2.3 
1 0.8 -19.8 
2 1.54 -23 
3 2.93 -2.4 





Figure 55: Trazodone calibration curve run (4.0 ng/mL point dropped due to being an outlier) 
03/16/2020. R2= 0.9895 
 
Table 47: Bias for trazodone calibration curve run 03/16/2020. 
Trazodone 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.10 0.22 121.8 
0.20 0.27 34.3 
0.40 0.35 -12.4 
1.00 0.84 -15.9 
2.00 1.90 -5.0 
3.00 3.12 3.9 






Figure 56: Buprenorphine calibration curve run 03/16/2020. R2= 0.9875 
 
Table 48: Bias for buprenorphine calibration curve run 03/16/2020. 
Buprenorphine 
Theoretical Conc. (ng/mL) Calc. Conc. (ng/mL) Bias (%) 
0.1 0.26 157.2 
0.2 0.31 54.6 
0.4 0.4 1.2 
1 0.85 -15.3 
2 1.76 -12.2 
3 2.91 -3 
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